ADG126 Mono + ADG126-anti PD1 + ADG126-ADG106

Phase 1/2Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Advanced/Metastatic Solid Tumors

Conditions

Advanced/Metastatic Solid Tumors

Trial Timeline

Mar 15, 2021 → May 17, 2024

NCT ID

NCT04645069

About ADG126 Mono + ADG126-anti PD1 + ADG126-ADG106

ADG126 Mono + ADG126-anti PD1 + ADG126-ADG106 is a phase 1/2 stage product being developed by Adagene for Advanced/Metastatic Solid Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT04645069. Target conditions include Advanced/Metastatic Solid Tumors.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04645069	Phase 1/2	Completed	Mar 15, 2021	May 17, 2024	Advanced/Metastatic Solid Tumors

Competing Products

20 competing products in Advanced/Metastatic Solid Tumors

See all competitors

Product	Company	Stage	Hype Score
Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib	Sun Pharmaceutical	Phase 1	33
Pembrolizumab + Lenvatinib + Oxaliplatin + Capecitabine + Leucovorin (or Levoleucovorin) + 5-FU	Eisai	Phase 3	77
PF-05082566 + KW-0761	Kyowa Kirin	Phase 1	33
eftilagimod alfa + carboplatin plus paclitaxel + cisplatin or carboplatin + pemetrexed + pembrolizumab (KEYTRUDA®)	Merck	Phase 3	77
MK-4464 + Pembrolizumab + 89Zr-MK-4464	Merck	Phase 1	33
ADG126 + Pembrolizumab (KEYTRUDA®) + Standard of Care (Trifluridine/Tipiracil-Bevacizumab) + Standard of care (Fruquintinib)	Merck	Phase 1/2	41
Selumetinib + Pembrolizumab	Merck	Phase 1	33
BJ-001 + Pembrolizumab	Merck	Phase 1	33
ADG116	Merck	Phase 1	33
Gebasaxturev IV + Gebasaxturev ITu + Pembrolizumab	Merck	Phase 2	52
ADU-S100 + ipilimumab	Novartis	Phase 1	33
simlukafusp alfa + Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody + Gemcitabine + Vinorelbine	Roche	Phase 2	52
Selicrelumab + Vanucizumab + Bevacizumab	Roche	Phase 1	33
AMG 510	Amgen	Phase 1	32
PF-08634404 + Sigvotatug Vedotin + Combination Agent 1	Pfizer	Phase 1/2	40
PF-08046876	Pfizer	Phase 1	32
Capecitabine + Sunitinib	Pfizer	Phase 2	51
IBI308	Innovent Biologics	Phase 1	32
MM-121 + Paclitaxel	Sanofi	Phase 1	32
Ubamatamab + REGN7075 + Sarilumab	Regeneron Pharmaceuticals	Phase 2	51

Other Products from Adagene

ADG126 + PembrolizumabPhase 2

ADG106 injection + PD-1 antibody injectionPhase 1/2

ADG106 + Doxorubicin + Cyclophosphamide + PaclitaxelPhase 1/2

ADG116Phase 1

ADG206Phase 1